 SAN FRANCISCO, May 11, 2022 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurixs president and chief executive officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18th, 2022 at 11:00 a.m. ET. 